Kennedy's op-ed defending the ACIP removal, asserting that most committee members had received substantial pharmaceutical funding and citing historical conflict findings.
Most of ACIP's members have received substantial funding from pharmaceutical companies
Kennedy's op-ed defending the ACIP removal, asserting that most committee members had received substantial pharmaceutical funding and citing historical conflict findings. original ran in the Wall Street Journal. The central statistic was independently fact-checked as misapplied (MME-36).